Perspectives
Nature Reviews Cancer 3, 303-309 (April 2003) | doi:10.1038/nrc1047
Opinion: Improving the evaluation of new cancer treatments: challenges and opportunities
Mace L. Rothenberg1, David P. Carbone1 & David H. Johnson1 About the authors
Abstract
There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?
Author affiliations
- Mace L. Rothenberg, David P. Carbone and David H. Johnson are at the Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee 37232-6307, USA.
Correspondence to: Mace L. Rothenberg1 Email: mace.rothenberg@vanderbilt.edu
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated RESEARCH |
